Table 3.
Baseline demographics of patient population and comparison of pulmonary function tests (PFTs), lung transplantation or death, and transplant-free survival time between PPI treatment group and control group
| Items | PPI treatment group (n = 130) | Control group (n = 85) | p-value |
|---|---|---|---|
| Age (years) | 66 (55–73) | 67 (61–76) | 0.112 |
| Male gender | 81 (62.3) | 54 (63.5) | 0.856 |
| Ethnicity (white, non-hispanic) | 93 (71.5) | 69 (81.2) | 0.109 |
| Surgical lung biopsy | 61 (46.9) | 35 (41.2) | 0.407 |
| BMI (kg/m2) | 27.7 (24.5–32.5) | 27.8 (25.4–30.8) | 0.945 |
| Smoking history (pack years) | 6 (0–25) | 5 (0–30) | 0.850 |
| Pulmonary hypertension | 22 (16.9) | 19 (22.4) | 0.333 |
| Lung function test | |||
| FVC% predicted | 65 (54–75) | 62 (51–77) | 0.440 |
| DLCO% predicted | 52 (42–65) | 47 (36–57) | 0.064 |
| Patients with lung transplantation or death | 77 (59.2) | 63 (74.1) | 0.025 |
| Transplant-free survival (years) | 3.4 (1.8–5.3) | 2.0 (1.2–4.1) | 0.001 |
Data are presented as median (25th–75th percentile) or number (percentage).